All In Biotech

Drug Trial Radar · NCT01061151

Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

Breastfeeding Version of the PROMISE Study (Promoting Maternal and Infant Survival Everywhere)

Last checked: Nov 19, 2026Latest source record: Feb 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 3,747 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,747

Actual

Start

Mar 1, 2011

Primary completion

Sep 30, 2016

Study completion Sep 30, 2016

Sponsor

Sponsor type
NIH
First posted
Feb 2, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (investigator, outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study was to examine, in an integrated and comprehensive fashion, three critical questions currently facing HIV-infected pregnant and postpartum women and their infants: 1. What is the optimal intervention for the prevention of antepartum and intrapartum transmission of HIV? 2. What is the optimal intervention for the prevention of postpartum transmission in breastfeeding (BF) infants? 3. What is the optimal intervention for the preservation of maternal health after the risk period for prevention of mother-to-child-transmission ends (either at delivery or cessation of BF)? The overall PROMISE protocol had three separate interventional components to address each of these three questions and was conducted at locations in Africa and other parts of the world. Due to variations in the standard of care for HIV-infected pregnant and postpartum women and their infants at different sites, not all of these questions were relevant. Therefore, two separate versions of the PROMISE protocol were developed, each containing only the relevant components. The 1077BF protocol was used at sites where the standard method of infant feeding was breastfeeding, whereas the 1077FF protocol was used at sites where the standard method of infant feeding was formula feeding. The analyses were collapsed across the two protocol versions, and therefore the summaries contain the results of the 1077BF and/or the 1077FF protocols.

Conditions

  • HIV Infections

Interventions

  • Zidovudine (ZDV)Drug

    300 mg twice daily

  • Nevirapine (NVP): Antepartum MothersDrug

    200 mg at onset of labor

  • Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tailDrug

    200 mg/300 mg x 2 tablets at onset of labor or as soon as possible thereafter; 200 mg/300 mg orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.

  • Lamivudine-Zidovudine (3TC-ZDV)Drug

    150 mg/300 mg twice daily

  • Lopinavir-ritonavir (LPV-RTV)Drug

    400 mg/100 mg twice daily beginning at \>= 14 weeks gestation; 600 mg/150 mg twice daily beginning at \>= 28 weeks gestation or at next visit (during third trimester) through delivery; 400 mg/100 mg twice daily after delivery up to 14 days postpartum.

  • Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])Drug

    200 mg/300 mg

  • Nevirapine (NVP): Infant short-courseDrug

    Oral suspension (dosing according to birth weight) once a day through 42 days of age or through the week 6 visit, whichever is later.

  • Nevirapine (NVP): Infant extendedDrug

    Oral suspension (dosing according to birth weight) once a day from 6 (up to 14) days of age until there was no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever came first.

  • No InterventionOther

    Women registered before/during labor received the full Antepartum Arm A regimen. Women registered after labor, and who received nevirapine outside of the study, received the Emtricitabine-tenofovir disoproxil fumarate (Truvada \[TRV\]) tail.

  • Discontinue triple ARVsOther

    ARVs were discontinued. When protocol specified criteria were met, mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).

  • Continue triple ARVsOther

    Mothers could be prescribed any licensed antiretroviral medication, as long as the treatment met the definition of HAART (three ARV drugs from two or more drug classes).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Antepartum Component: Number of Confirmed Infant HIV InfectionsTime frame: Measured at birth or Week 1 study visit
  2. Antepartum Component: Number of Mothers With Grade 3 or Higher Toxicities and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse EventsTime frame: Measured through the Week 1 postpartum study visit
  3. Antepartum Component: Number of Mothers With Obstetrical ComplicationsTime frame: Measured through the Week 1 postpartum study visit
  4. Antepartum Component: Number of Mothers With Adverse Pregnancy Outcomes (e.g.,Stillbirth, Preterm Delivery (< 37 Weeks), Low Birth Weight (< 2,500 Grams), and Congenital Anomalies)Time frame: Measured at birth
  5. Postpartum Component: Incidence of Confirmed Infant HIV InfectionTime frame: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first
  6. Postpartum Component: Incidence of Grade 3 or Higher Adverse Events and Selected Grade 2 Hematologic, Renal, and Hepatic Adverse EventsTime frame: Measured through site recommended duration of breastfeeding, complete cessation of breastfeeding or 18 months of age, whichever comes first
  7. Maternal Health Component: Incidence of Progression to AIDS-defining Illness or DeathTime frame: From study entry until July 7, 2015, an average of 94 weeks of follow-up.

Locations

14 sites in 7 countries. Site status is shown where the registry gives one.

  • Byramjee Jeejeebhoy Medical College (BJMC) CRS

    Pune, Maharashtra, India

  • Blantyre CRS

    Blantyre, Malawi

  • Malawi CRS

    Lilongwe, Malawi

  • Soweto IMPAACT CRS

    Johannesburg, Gauteng, South Africa

  • Shandukani Research CRS

    Johannesburg, Gauteng, South Africa

  • Durban Paediatric HIV CRS

    Durban, KwaZulu-Natal, South Africa

  • Umlazi CRS

    Durban, KwaZulu-Natal, South Africa

  • Family Clinical Research Unit (FAM-CRU) CRS

    Cape Town, Western Cape, South Africa

  • Kilimanjaro Christian Medical Centre (KCMC)

    Moshi, Tanzania

  • MU-JHU Research Collaboration (MUJHU CARE LTD) CRS

    Kampala, Uganda

  • George CRS

    Lusaka, Zambia

  • Seke North CRS

    Chitungwiza, Zimbabwe

  • St Mary's CRS

    Chitungwiza, Zimbabwe

  • Harare Family Care CRS

    Harare, Zimbabwe

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.